Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism

Inclusion criteria 1. More than or equal to 18 years old and less than 80 years old; 2. Acute ischemic stroke, brain magnetic resonance imaging showed non lacunar infarction (subcortical infarction less than or equal to 1.5 cm); 3. Onset within 72 hours; 4. Patients or their family members are willing to sign the informed consent. Exclusion criteria 1. Intracranial hemorrhage: cerebral hemorrhage, subarachnoid hemorrhage, etc.; 2. Transient ischemic attack; 3. Lacunar infarction; 4. History of acute stroke within 6 months; 5. Clear diagnosis of other causes of ischemic stroke (arterial dissection, arteritis, vasospasm, etc.); 6. The acute infarcts lesion more than one-half lobe in size; 7. Preceding modified Rankin Scale (mRS) score ≥ 2; 8. Cumulative usage of traditional Chinese medicine which activating blood circulation more than 3 times after onset, including but not limited to: Danhong, Xueshuantong, Xuesaitong, Ginkgo biloba, sodium ozagrel, Salvia miltiorrhiza, ligustrazine, Erigeron breviscapus, etc; 9. Chronic liver disease, liver and kidney dysfunction, lifted alanine aminotransferase (\>3 times the ULN), lifted serum creatinine (\>2 times the ULN）; 10. History of coagulopathy, systemic bleeding, thrombocytopenia or neutropenia; 11. Blood pressure \>90/60 mmHg or ≤220/120 mmHg after treatment; 12. Serious heart or lung disease, in the judgment of clinical study staff, would not suitable to participant in the trial; 13. Patients with atrial fibrillation who were scheduled or likely to receive anticoagulant therapy with unfractionated heparin or low molecular weight heparin within 2 weeks after randomization 14. A medical condition likely to limit survival to less than three months or any other condition judged by the clinic team to likely limit the adherence to study procedures; 15. Known allergies for ingredients of the drug, allergy history for food or drug; 16. Pregnant, currently trying to become pregnant, or of child-bearing potential and not using birth control; 17. Participation in another clinical trial within 30 days; 18. Unable to understand and/or comply with the study procedures and/or follow-up studies due to mental illness, cognitive or emotional disorders. Subgroup Exclusion Criteria 1. History of atrial fibrillation 2. Atrial fibrillation in 12-lead electrocardiogram (ECG); 3. Heart rate monitoring (dynamic electrocardiogram telemetry) up to 20 hours or more detected atrial fibrillation for 6 minutes or more; 4. Intracardiac thrombosis in thoracic or esophageal echocardiography; 5. Occlusion or proximal vessel infarction for more than 50%.